Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age.

Alyea EP, Kim HT, Ho V, Cutler C, Gribben J, DeAngelo DJ, Lee SJ, Windawi S, Ritz J, Stone RM, Antin JH, Soiffer RJ.

Blood. 2005 Feb 15;105(4):1810-4. Epub 2004 Sep 30.

3.

Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect.

Alyea E, Weller E, Schlossman R, Canning C, Mauch P, Ng A, Fisher D, Gribben J, Freeman A, Parikh B, Richardson P, Soiffer R, Ritz J, Anderson KC.

Bone Marrow Transplant. 2003 Dec;32(12):1145-51. Review.

PMID:
14647268
4.

Nonmyeloablative stem cell transplantation and cell therapy for malignant and non-malignant diseases.

Resnick IB, Shapira MY, Slavin S.

Transpl Immunol. 2005 Aug;14(3-4):207-19. Epub 2005 Apr 26. Review.

PMID:
15982565
5.

Can reduced-intensity allogeneic transplantation cure older adults with AML?

Storb R.

Best Pract Res Clin Haematol. 2007 Mar;20(1):85-90. Review.

PMID:
17336258
6.
7.

Reduced-intensity conditioning followed by allogeneic hematopoietic stem cell transplantation in myelofibrosis.

Alchalby H, Kröger N.

Curr Hematol Malig Rep. 2010 Apr;5(2):53-61. doi: 10.1007/s11899-010-0044-z. Review.

PMID:
20425397
8.

Critical review on non-myeloablative stem cell transplantation (NST).

Anagnostopoulos A, Giralt S.

Crit Rev Oncol Hematol. 2002 Nov;44(2):175-90. Review.

PMID:
12413634
9.

[Hematopoietic stem cell transplantation after nonmyeloablative conditioning].

Carella AM.

Recenti Prog Med. 2001 May;92(5):322-6. Review. Italian.

PMID:
11413889
10.

Myeloablative conditioning regimens for AML allografts: 30 years later.

Gupta V, Lazarus HM, Keating A.

Bone Marrow Transplant. 2003 Nov;32(10):969-78. Review.

PMID:
14595384
11.

Current status of hematopoietic stem cell transplantation after nonmyeloablative conditioning.

Baron F, Sandmaier BM.

Curr Opin Hematol. 2005 Nov;12(6):435-43. Review.

PMID:
16217159
12.

Allogeneic stem cell transplantation in follicular lymphoma.

Khouri IF.

Best Pract Res Clin Haematol. 2011 Jun;24(2):271-7. doi: 10.1016/j.beha.2011.03.008. Epub 2011 May 5. Review.

13.

Acute kidney injury following HCT: incidence, risk factors and outcome.

Lopes JA, Jorge S.

Bone Marrow Transplant. 2011 Nov;46(11):1399-408. doi: 10.1038/bmt.2011.46. Epub 2011 Mar 7. Review.

PMID:
21383682
14.

Reduced intensity allogeneic hematopoietic transplantation is an established standard of care for treatment of older patients with acute myeloid leukemia.

Champlin R.

Best Pract Res Clin Haematol. 2013 Sep;26(3):297-300. doi: 10.1016/j.beha.2013.10.011. Epub 2013 Oct 16. Review.

PMID:
24309534
15.
16.

Myeloablative chemotherapy with stem cell rescue for the treatment of primary systemic amyloidosis: a status report.

Gertz MA, Lacy MQ, Dispenzieri A.

Bone Marrow Transplant. 2000 Mar;25(5):465-70. Review.

17.

[High dose treatments and preparatory regimens prior to haematopoietic stem cell transplantation].

Tomíška M.

Vnitr Lek. 2012 Jul-Aug;58(7-8):581-6. Review. Czech.

PMID:
23067183
18.

Immunotherapy of solid tumors: nonmyeloablative allogeneic stem cell transplantation.

Childs RW.

MedGenMed. 2002 Jun 26;4(3):13. Review. No abstract available.

20.

Acute kidney injury in hematopoietic cell transplantation.

Kogon A, Hingorani S.

Semin Nephrol. 2010 Nov;30(6):615-26. doi: 10.1016/j.semnephrol.2010.09.009. Review.

Supplemental Content

Support Center